Target No. 2
CANCER Cancer researchers at Fox Chase Cancer Center and Fels Institute for Cancer Research & Molecular Biology aim to understand the etiology and pathogenesis of cancer and to translate their findings into targeted anti-cancer therapies. One of only 41 National Cancer Institute-designated Comprehensive Cancer Centers in the U.S., Fox Chase has long been at the forefront of scientific discovery. In 2012, Fox Chase became part of Temple University Health System, opening the door to a range of new collaborations. Researchers at Fox Chase can now, for example, capitalize on unique technical capabilities residing within the Temple Proteomics Facility and Temple School of Pharmacy’s Moulder Center for Drug Development Research. New collaborations among Temple’s cancer researchers are already far advanced in the critically important field of epigenetics. To jump-start more collaborations— in areas such as cancer signaling, synthetic lethality, and personalized medicine— Temple leadership recently created a $1 million venture fund to seed the most promising ideas.
CANCER
27